The Experts below are selected from a list of 12987 Experts worldwide ranked by ideXlab platform
S Sinha - One of the best experts on this subject based on the ideXlab platform.
-
withdrawal of penicillamine from Zinc Sulphate penicillamine maintenance therapy in wilson s disease promising safe and cheap
Journal of the Neurological Sciences, 2008Co-Authors: S Sinha, A B TalyAbstract:Abstract Background Penicillamine, once considered the cornerstone of treatment for Wilson disease (WD), is rather expensive and toxic, and often causes neurological worsening. Zinc Sulphate, aiming at the treatment of free-copper toxicosis, has emerged as effective, safe and cheap alternative. Aim To assess the effect of withdrawal of penicillamine from maintenance treatment with penicillamine and Zinc Sulphate. Patients and methods 45 patients of WD (M:F: 28:17; age at diagnosis: 13.5 ± 63 years), on both penicillamine (P) and Zinc Sulphate (Zn), couldn’t continue penicillamine due to financial constraints. Their clinical data, disability and impairment scores (Schwab and England (SE p = 0.4), NSS (1.8 ± 3.1 vs. 1.5 ± 2.3; p = 0.03) and SE p = 0.03). There were no adverse effects. Conclusions Withdrawal of penicillamine from Zinc Sulphate/penicillamine maintenance therapy for patients with Wilson's disease was effective, safe and economic, for almost all patients. This retrospective study reiterates that Zinc Sulphate may be used as a preferred mode of treatment for patients with Wilson's disease.
-
Withdrawal of penicillamine from Zinc Sulphate-penicillamine maintenance therapy in Wilson's disease: promising, safe and cheap.
Journal of the neurological sciences, 2007Co-Authors: S Sinha, A B TalyAbstract:Penicillamine, once considered the cornerstone of treatment for Wilson disease (WD), is rather expensive and toxic, and often causes neurological worsening. Zinc Sulphate, aiming at the treatment of free-copper toxicosis, has emerged as effective, safe and cheap alternative. To assess the effect of withdrawal of penicillamine from maintenance treatment with penicillamine and Zinc Sulphate. 45 patients of WD (M:F: 28:17; age at diagnosis: 13.5+/-63 years), on both penicillamine (P) and Zinc Sulphate (Zn), couldn't continue penicillamine due to financial constraints. Their clinical data, disability and impairment scores (Schwab and England (S&E) score, Neurological Symptom Score (NSS), and Chu staging) and follow-up data of patients maintained only on Zinc Sulphate were recorded. Majority of patients (84.4%) had neuropsychiatric manifestations. The mean duration of treatment with penicillamine (P) and Zinc Sulphate (P+Zn), before stopping penicillamine, was 107.4+/-67.3 months. 40 patients improved variably, while the rest didn't. They received only Zinc Sulphate for 27.2+/-8.5 months (range: 12 to 34) and 44 patients (97.7%) remained status quo or improved marginally. Only one patient reported worsening in dysarthria. Their disability and impairment scores during combination (penicillamine and Zinc Sulphate) and Zn alone were: Chu (1.3+/-0.5 vs. 1.5+/-1.9; p=0.4), NSS (1.8+/-3.1 vs. 1.5+/-2.3; p=0.03) and S&E (96.4+/-5.6 vs. 98.6+/-3.5; p=0.03). There were no adverse effects. Withdrawal of penicillamine from Zinc Sulphate/penicillamine maintenance therapy for patients with Wilson's disease was effective, safe and economic, for almost all patients. This retrospective study reiterates that Zinc Sulphate may be used as a preferred mode of treatment for patients with Wilson's disease.
-
Withdrawal of penicillamine from Zinc Sulphate–penicillamine maintenance therapy in Wilson's disease: Promising, safe and cheap
Journal of the Neurological Sciences, 2007Co-Authors: S Sinha, TalyAbstract:Abstract Background Penicillamine, once considered the cornerstone of treatment for Wilson disease (WD), is rather expensive and toxic, and often causes neurological worsening. Zinc Sulphate, aiming at the treatment of free-copper toxicosis, has emerged as effective, safe and cheap alternative. Aim To assess the effect of withdrawal of penicillamine from maintenance treatment with penicillamine and Zinc Sulphate. Patients and methods 45 patients of WD (M:F: 28:17; age at diagnosis: 13.5 ± 63 years), on both penicillamine (P) and Zinc Sulphate (Zn), couldn’t continue penicillamine due to financial constraints. Their clinical data, disability and impairment scores (Schwab and England (SE p = 0.4), NSS (1.8 ± 3.1 vs. 1.5 ± 2.3; p = 0.03) and SE p = 0.03). There were no adverse effects. Conclusions Withdrawal of penicillamine from Zinc Sulphate/penicillamine maintenance therapy for patients with Wilson's disease was effective, safe and economic, for almost all patients. This retrospective study reiterates that Zinc Sulphate may be used as a preferred mode of treatment for patients with Wilson's disease.
A B Taly - One of the best experts on this subject based on the ideXlab platform.
-
withdrawal of penicillamine from Zinc Sulphate penicillamine maintenance therapy in wilson s disease promising safe and cheap
Journal of the Neurological Sciences, 2008Co-Authors: S Sinha, A B TalyAbstract:Abstract Background Penicillamine, once considered the cornerstone of treatment for Wilson disease (WD), is rather expensive and toxic, and often causes neurological worsening. Zinc Sulphate, aiming at the treatment of free-copper toxicosis, has emerged as effective, safe and cheap alternative. Aim To assess the effect of withdrawal of penicillamine from maintenance treatment with penicillamine and Zinc Sulphate. Patients and methods 45 patients of WD (M:F: 28:17; age at diagnosis: 13.5 ± 63 years), on both penicillamine (P) and Zinc Sulphate (Zn), couldn’t continue penicillamine due to financial constraints. Their clinical data, disability and impairment scores (Schwab and England (SE p = 0.4), NSS (1.8 ± 3.1 vs. 1.5 ± 2.3; p = 0.03) and SE p = 0.03). There were no adverse effects. Conclusions Withdrawal of penicillamine from Zinc Sulphate/penicillamine maintenance therapy for patients with Wilson's disease was effective, safe and economic, for almost all patients. This retrospective study reiterates that Zinc Sulphate may be used as a preferred mode of treatment for patients with Wilson's disease.
-
Withdrawal of penicillamine from Zinc Sulphate-penicillamine maintenance therapy in Wilson's disease: promising, safe and cheap.
Journal of the neurological sciences, 2007Co-Authors: S Sinha, A B TalyAbstract:Penicillamine, once considered the cornerstone of treatment for Wilson disease (WD), is rather expensive and toxic, and often causes neurological worsening. Zinc Sulphate, aiming at the treatment of free-copper toxicosis, has emerged as effective, safe and cheap alternative. To assess the effect of withdrawal of penicillamine from maintenance treatment with penicillamine and Zinc Sulphate. 45 patients of WD (M:F: 28:17; age at diagnosis: 13.5+/-63 years), on both penicillamine (P) and Zinc Sulphate (Zn), couldn't continue penicillamine due to financial constraints. Their clinical data, disability and impairment scores (Schwab and England (S&E) score, Neurological Symptom Score (NSS), and Chu staging) and follow-up data of patients maintained only on Zinc Sulphate were recorded. Majority of patients (84.4%) had neuropsychiatric manifestations. The mean duration of treatment with penicillamine (P) and Zinc Sulphate (P+Zn), before stopping penicillamine, was 107.4+/-67.3 months. 40 patients improved variably, while the rest didn't. They received only Zinc Sulphate for 27.2+/-8.5 months (range: 12 to 34) and 44 patients (97.7%) remained status quo or improved marginally. Only one patient reported worsening in dysarthria. Their disability and impairment scores during combination (penicillamine and Zinc Sulphate) and Zn alone were: Chu (1.3+/-0.5 vs. 1.5+/-1.9; p=0.4), NSS (1.8+/-3.1 vs. 1.5+/-2.3; p=0.03) and S&E (96.4+/-5.6 vs. 98.6+/-3.5; p=0.03). There were no adverse effects. Withdrawal of penicillamine from Zinc Sulphate/penicillamine maintenance therapy for patients with Wilson's disease was effective, safe and economic, for almost all patients. This retrospective study reiterates that Zinc Sulphate may be used as a preferred mode of treatment for patients with Wilson's disease.
Taly - One of the best experts on this subject based on the ideXlab platform.
-
Withdrawal of penicillamine from Zinc Sulphate–penicillamine maintenance therapy in Wilson's disease: Promising, safe and cheap
Journal of the Neurological Sciences, 2007Co-Authors: S Sinha, TalyAbstract:Abstract Background Penicillamine, once considered the cornerstone of treatment for Wilson disease (WD), is rather expensive and toxic, and often causes neurological worsening. Zinc Sulphate, aiming at the treatment of free-copper toxicosis, has emerged as effective, safe and cheap alternative. Aim To assess the effect of withdrawal of penicillamine from maintenance treatment with penicillamine and Zinc Sulphate. Patients and methods 45 patients of WD (M:F: 28:17; age at diagnosis: 13.5 ± 63 years), on both penicillamine (P) and Zinc Sulphate (Zn), couldn’t continue penicillamine due to financial constraints. Their clinical data, disability and impairment scores (Schwab and England (SE p = 0.4), NSS (1.8 ± 3.1 vs. 1.5 ± 2.3; p = 0.03) and SE p = 0.03). There were no adverse effects. Conclusions Withdrawal of penicillamine from Zinc Sulphate/penicillamine maintenance therapy for patients with Wilson's disease was effective, safe and economic, for almost all patients. This retrospective study reiterates that Zinc Sulphate may be used as a preferred mode of treatment for patients with Wilson's disease.
Khalifa E Sharquie - One of the best experts on this subject based on the ideXlab platform.
-
Oral Zinc Sulphate in Treatment of Alopecia Areata (Double Blind; Cross- Over Study)
Journal of Clinical & Experimental Dermatology Research, 2014Co-Authors: Khalifa E Sharquie, Adil A. Noaimi, Emad R ShwailAbstract:Background: Alopecia areata is a common autoimmune disease that encountered world-wide. Many modalities have been used but no one was universally effective. Zinc Sulphate has been used in the treatment of many skin diseases. Objective: To establish the effectiveness of oral Zinc Sulphate in the treatment of patchy alopecia areata Patients and Methods: Patients with alopecia areata who attended the Department of Dermatology-Baghdad Teaching Hospital was recruited into randomized, placebo-controlled, double-blind cross- over trial between February 2008 and September 2009. Patients were randomly allocated to receive either Zinc Sulphate 5mg /kg/day in three divided doses (Group A) or identical placebo capsules (Group B). Zinc Sulphate and placebo capsules were given in a double-blind manner, following 3 months of starting the treatment, the patients crossed over, i.e. patients on Zinc Sulphate shifted to placebo and vice versa. Results: One hundred patients (60 males and 40 females) with patchy AA met the inclusion criteria and enrolled for the study. Sixty-seven patients completed the study, 41(61%) males and 26 (39%) females, their ages ranged from 1.6 - 68 (22.031 ± 14.8505) years. Duration of the disease ranged from 1 - 48 (14.4 ±14.8875) weeks. In group A, at the end of third month, complete hair re-growth with terminal hairs have been obtained in 22 (59.45%) patients. After shifting to placebo treatment the hair continued to grow without relapse and at the end of sixth month, the complete hair re-growth was occurred in 23(62.16%) patients. In group B, at the end of third month, complete hair re-growth had been obtained in 3 (10%) patients. While, after shifting to Zinc Sulphate the complete hair re-growth obtained in 20 (66.67%) patients. No important side effects were reported apart from mild gastric upset in 8 (11.9%) patients. Conclusion: Oral Zinc Sulphate is one of the effective treatment options for AA with low relapse rate after stopping of the treatment.
-
topical Zinc Sulphate solution for treatment of viral warts
Saudi Medical Journal, 2007Co-Authors: Khalifa E Sharquie, Alaa A Khorsheed, Adil A AlnuaimyAbstract:OBJECTIVES To assess the efficacy and safety of topical Zinc Sulphate solution in the treatment of plane and common warts. METHODS This study consisted of a pilot and double blinded clinical trails. This was carried out in the Department of Dermatology and Venereology, Baghdad Teaching Hospital, Baghadad, Iraq during the period from December 2002 to October 2003. Ten patients with plane warts were enrolled in pilot-clinical trial, all patients used 10% w/v Zinc Sulphate solution topically, 3 times daily for 4 weeks while in the double blind trial, 90 patients were included (50 patients with common warts, 40 patients with plane warts). Patients were randomly used either topical 10% or 5% Zinc Sulphate solution or distilled water as a control topical therapy 3 times daily for 4 weeks. Full history and close clinical examination were performed to all patients before treatment. RESULTS In the pilot trial, the full response for plane warts was 80%, while the full response for patients with plane warts in double blinded trial was 85.7%, 42.8% and 10% for those using 10% and 5% Zinc Sulphate solutions and distilled water subsequently. The difference was statistically significant (p<0.008). The full response for patients with common warts were 11%, 5% and 0% for those who used 10% and 5% Zinc Sulphate solutions and distilled water respectively, the difference was statistically insignificant. No recurrence of warts occurred during follow up that ranged from 2-6 months after therapy. CONCLUSIONS Topical 10% Zinc Sulphate solution was a new effective and safe modality for treatment of plane warts.
-
Topical Zinc Sulphate solution for treatment of viral warts.
Saudi medical journal, 2007Co-Authors: Khalifa E Sharquie, Alaa A Khorsheed, Adil A. Al-nuaimyAbstract:OBJECTIVES To assess the efficacy and safety of topical Zinc Sulphate solution in the treatment of plane and common warts. METHODS This study consisted of a pilot and double blinded clinical trails. This was carried out in the Department of Dermatology and Venereology, Baghdad Teaching Hospital, Baghadad, Iraq during the period from December 2002 to October 2003. Ten patients with plane warts were enrolled in pilot-clinical trial, all patients used 10% w/v Zinc Sulphate solution topically, 3 times daily for 4 weeks while in the double blind trial, 90 patients were included (50 patients with common warts, 40 patients with plane warts). Patients were randomly used either topical 10% or 5% Zinc Sulphate solution or distilled water as a control topical therapy 3 times daily for 4 weeks. Full history and close clinical examination were performed to all patients before treatment. RESULTS In the pilot trial, the full response for plane warts was 80%, while the full response for patients with plane warts in double blinded trial was 85.7%, 42.8% and 10% for those using 10% and 5% Zinc Sulphate solutions and distilled water subsequently. The difference was statistically significant (p
-
TREATMENT OF VIRAL WARTS BY INTRALESIONAL INJECTION OF Zinc Sulphate
Annals of Saudi medicine, 2002Co-Authors: Khalifa E Sharquie, Adil A. Al-nuaimyAbstract:BACKGROUND: The aim of this study was to verify the efficacy of the intralesional injection of 2% Zinc Sulphate as compared to an injection of 7% hypertonic sodium chloride solution in the treatmen...
-
Oral Zinc Sulphate in the treatment of acute cutaneous leishmaniasis.
Clinical and experimental dermatology, 2001Co-Authors: Khalifa E Sharquie, Rafid A. Najim, Imad B Farjou, D. J. Al-timimiAbstract:A clinical trial to evaluate the efficiency of oral Zinc Sulphate in the treatment of cutaneous leishmaniasis was conducted. One-hundred and four patients with parasitologically proven cutaneous leishmaniasis were included in the trial. Patients were assigned randomly to receive 2.5, 5 or 10 mg/kg of Zinc Sulphate orally, and a control group of patients did not receive any treatment. All patients were followed up for 45 days. At the end of the follow-up period, lesions were assessed and parasitological proof of cure or otherwise was sought. Results showed that the cure rate for the 2.5 mg/kg group was 83.9%, for the 5 mg/kg treatment group it was 93.1% and for the 10 mg/kg treatment group it was 96.9%. No lesions in the control group showed any sign of healing during the follow-up period. Therefore, oral Zinc Sulphate can be recommended as a very safe therapy for cutaneous leishmaniasis.
Bikshandarkoil R. Srinivasan - One of the best experts on this subject based on the ideXlab platform.
-
Reinvestigation of growth of 2-aminopyridine bis thiourea Zinc Sulphate single crystal
Journal of Molecular Structure, 2019Co-Authors: Bikshandarkoil R. Srinivasan, Megha S. DeshpandeAbstract:Abstract In an earlier published paper, Srineevasan and Rajasekaran (J. Mol. Struc. 1048, (2013) 238–243) [1] reported to have grown a so called 2-aminopyridine bis thiourea Zinc Sulphate single crystal (1) by slow evaporation technique at room temperature. A reinvestigation of the reported crystal growth reaction reveals that addition of 2-aminopyridine into an aqueous solution containing Zinc Sulphate heptahydrate and thiourea in 1:2 mol ratio initially results in the formation of a white precipitate. Filtration of the precipitate followed by slow evaporation of the filtrate results in the crystallization of the known compound sulphatotris(thiourea)Zinc(II) (2) and NOT any 2-aminopyridine bis thiourea Zinc Sulphate.
-
On the existence of ethylenediaminetetraacetic acid (EDTA) doped Zinc Sulphate heptahydrate crystal
arXiv: Materials Science, 2015Co-Authors: Bikshandarkoil R. SrinivasanAbstract:It is argued that the ethylenediaminetetraacetic acid (EDTA) doped Zinc Sulphate heptahydrate crystal reported by Raja et al Spectrochim Acta 99A (2012) 23 is the well known Zinc Sulphate heptahydrate.
-
Reinvestigation of growth of 'L-valine Zinc Sulphate' crystal.
Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2014Co-Authors: Bikshandarkoil R. Srinivasan, Rita N. JyaiAbstract:A reinvestigation of the growth of l-valine Zinc Sulphate crystal is reported. The slow evaporation of an aqueous solution containing l-valine and Zinc Sulphate heptahydrate results in the fractional crystallization of l-valine and not the organic inorganic hybrid nonlinear optical l-valine Zinc Sulphate crystal, as reported by Puhal Raj and Ramachandra Raja (2012).
